Investors are still waiting to see whether hepatitis C developers Idenix Pharmaceuticals (IDIX) and Achillion Pharmaceuticals (ACHN) are taken out following similar deals for Pharmasset and Inhibitex .
FORBES: For Biotech, 'Fail' is Making a Big Comeback